ArticleDiscover oncology2025
Benign prostatic hyperplasia and risk of urological cancers: a prospective cohort study based on the UK biobank.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBenign prostatic hyperplasia (BPH) is considered a risk factor for certain urological cancers; however, current evidence remains ambiguous. This study aimed to assess the relationship between BPH and risk of urological cancers, including any potential causal connections.
methodsBetween 2006 and 2010, we identified 190,829 participants in the UK Biobank. We used the Cox proportional hazards regression model to calculate adjusted hazard ratios (HR) and 95% confidence intervals (95% CI). We balanced the covariate differences between the BPH and non-BPH groups using propensity score matching (PSM). We also performed a two-sample Mendelian randomization (MR) analysis to investigate the causal link between BPH and risks of urological cancers.
resultsParticipants with BPH had significantly higher risks of prostate cancer (PCa) (pre-PSM HR 1.28, 95% CI 1.20-1.36, n = 1,127 cases; post-PSM 1.30, 1.19-1.41), bladder cancer (BCa) (pre-PSM 1.49, 1.17-1.91, n = 79; post-PSM 1.92, 1.32-2.80) and renal cell carcinoma (RCC) (pre-PSM 1.29, 1.02-1.64, n = 79; post-PSM 1.41, 1.01-1.99) compared to non-BPH participants. MR analysis revealed that BPH has a positive causal effect on PCa (OR 1.002, 1.000-1.004) and BCa (OR 1.001, 1.000-1.002). This association between BPH and PCa or BCa is significantly moderated by age (P < 0.001), and is more pronounced in white individuals and those with sufficient physical activity.
conclusionsThis study revealed that people with BPH have a higher risk of PCa, RCC and BCa. There is a significant causal relationship between BPH and an increased risk of PCa and BCa.
trial registrationNot applicable. This study is a prospective observational analysis based on the UK Biobank cohort (application number 135237) and did not involve any interventional procedures that would require clinical-trial registration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.